0000899243-22-030735.txt : 20220909
0000899243-22-030735.hdr.sgml : 20220909
20220909164625
ACCESSION NUMBER: 0000899243-22-030735
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220908
FILED AS OF DATE: 20220909
DATE AS OF CHANGE: 20220909
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Henn Matthew R.
CENTRAL INDEX KEY: 0001767321
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 221236640
MAIL ADDRESS:
STREET 1: C/O SERES THERAPEUTICS, INC.
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-08
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001767321
Henn Matthew R.
C/O SERES THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
Stock Option (Right to Buy)
10.84
2022-09-08
4
A
0
35000
0.00
A
2022-09-08
2027-07-18
Common Stock
35000
35000
D
On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. Subject to the Reporting Person's continued service to the Issuer through each applicable vesting date, the option vests and becomes exercisable in two equal installments upon the satisfaction of certain performance criteria. On September 8, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in vesting of the option as to 35,000 shares.
Chief Scientific Officer and EVP
/s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn
2022-09-09